[Disclosure] Samsung Biologics (207940) Reports Q2 2024 Operating Profit of KRW 434.5B, Skyrocketing 71.5% YoY

Source Fact: Financial Supervisory Service DART / 2024-07-24

Disclosure Type: Earnings Release (Preliminary Results based on Consolidated Financial Statements)

💡 3-Second Summary

Samsung Biologics announced its preliminary Q2 2024 financial results, posting an impressive operating profit of approximately KRW 434.5B—a massive 71.45% surge YoY—while top-line revenue grew 33.56% to KRW 1.16T, pushing cumulative first-half revenue past the KRW 2.0T milestone.

📊 1. [Summary of Core Disclosure & Key Figures]

Preliminary consolidated earnings for Q2 2024. (Label matching verified: Revenue $\ge$ Operating Profit)

• Q2 2024 Quarter-Specific Performance (Unit: KRW Million)
  • Revenue: 1,156,904 (approx. KRW 1.16T)
    • QoQ: +22.18% / YoY: +33.56%
  • Operating Profit: 434,511 (approx. KRW 434.5B)
    • QoQ: +96.35% / YoY: +71.45%
  • Profit Before Income Tax: 464,960 (approx. KRW 465.0B)
    • QoQ: +93.67% / YoY: +85.01%
  • Net Profit: 317,992 (approx. KRW 318.0B)
    • QoQ: +77.29% / YoY: +71.99%
• Q2 2024 Cumulative Performance (H1 Jan-Jun Total, Unit: KRW Million)
  • Cumulative Revenue: 2,103,808 (approx. KRW 2.10T) | +32.56% vs. prior year cumulative
  • Cumulative Operating Profit: 655,810 (approx. KRW 655.8B) | +47.31% vs. prior year cumulative
  • Cumulative Net Profit: 497,354 (approx. KRW 497.4B) | +52.26% vs. prior year cumulative
• Note: The disclosure does not state specific reasons for the performance fluctuations. These figures are preliminary and subject to change pending an independent external audit.

📈 2. [Expert Insight: Implications for Investors]

• Validation of Elite Fundamental Strength: Surpassing KRW 1.15T in quarterly revenue matched with a 71.45% YoY surge in operating profit serves as a powerful validation of the company’s underlying Fundamental. Generating over KRW 2.10T in cumulative revenue within just the first half (H1) of the year confirms top-tier execution in both volume expansion and profitability.
• Margin Expansion & Operating Leverage: While Q2 revenue increased by 22.18% sequentially from Q1, operating profit nearly doubled (+96.35% QoQ). Although specific drivers were omitted in the filing, a favorable batch recognition schedule for high-margin products, enhanced operating leverage from rising facility utilization rates, or supportive FX tailwinds could have exerted a strong positive impact on margin expansion.
• Investor Consideration: This across-the-board surge in growth and profitability metrics is likely to be viewed very favorably by market participants. However, because the formal text omits granular explanations for the profit spike, shareholders are advised to review the concurrent IR presentations or earnings conference calls to cross-reference plant-by-plant utilization rates and operational cost efficiencies.

📝 Editor’s Comment (by K-STOCK Editor)

Samsung Biologics just dropped an absolute monster of a quarterly report! Seeing operating profit nearly double (+96.35%) from Q1 while skyrocketing over 71% year-over-year is a breathtaking showcase of operational leverage. By racking up over KRW 2.1 trillion in revenue in just the first half (H1) of the year alone, the company has decisively proven the formidable cash-generating power of its mega-scale manufacturing engines running at full throttle. This scoreboard is a pure demonstration of industry dominance, clearly explaining why global biopharma demand continues to flood into Samsung Biologics’ facilities.

📢 Disclaimer & Source Information

Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.

Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.